TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy

Peters, Christopher A.; Stock, Richard G.; Cesaretti, Jamie A.; Atencio, David P.; Peters, Sheila Annie; Burri, Ryan J.; Stone, Nelson N.; Ostrer, Harry; Rosenstein, Barry S.

doi:10.1016/j.ijrobp.2007.05.023

Cited by 61 publications

(36 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, several observations support the hypothesis that single nucleotide polymorphisms (SNPs) in genes related to the biological response to ionizing radiation may affect clinical radiosensitivity [5,10,11,15,20,47]. In prostate cancer patients, single nucleotide polymorphisms (SNPs) in candidate genes involved in DNA repair, steroid metabolism, and fibrotic tissue remodeling have been associated with the development of late toxicity after radiation therapy [9,10,14,37].…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 91%

“…TGF-ß polymorphisms have previously been associated with the risk of radiation-induced late toxicity [2,37,38,51]. Polymorphisms in the VEGF gene have also been identified with some of them leading to altered activity [1,8,26].…”

Section: Introductionmentioning

confidence: 99%

Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Additionally, to our knowledge, no AURKA SNPs have been reported in any prostate cancer genome wide association studies. Further studies are necessary given the prognostic utility of SNPs in predicting cancer risk and recurrence [11,12], based on the premise that these SNP studies will enhance the accuracy of existing prognostic nomograms that incorporate clinical variables such as clinical stage, Gleason score, and prostate-specific antigen (PSA) levels [13].…”

Section: Introductionmentioning

confidence: 99%

The Aurora Kinase A Polymorphisms are not Associated with Recurrence-free Survival in Prostate Cancer Patients

Jaboin

Ausborn

Hwang

et al. 2012

JCST

View full text Add to dashboard Cite

Background: The purpose of this study was to investigate the association between haplotype-tagging single nucleotide polymorphisms (SNPs) within the Aurora Kinase A (AURKA) gene and prostate cancer outcomes in patients with clinically localized prostate cancer. Methods:Four intronic haplotype-tagging SNPs within the AURKA gene were individually selected and examined in regard to their influence on clinical outcomes in 212 patients who underwent radical prostatectomy as first-line treatment. Haplotype-tagging SNPs were selected using the ABI SNP Browser to cover SNPs with an r 2 of 0.90 or greater in the AURKA gene with a minor allele frequency of at least 0.25. Results:In our study, a log-rank univariate analysis was performed to identify significant associations between probability of recurrence-free survival or disease-free survival and known prognostic indicators as well as AURKA genotypes. The prognostic indicators Gleason grade, surgical margin, extracapsular extension, and disease stage were associated with recurrence-free survival (all p<0.001). Only Gleason grade was associated with disease-free survival (p<0.001). No associations were found for the SNPs rs1468055, rs8117896, rs2064863, and rs1468056 analyzed for either RFS (p=0.7213, p=0.5140, p=0.0714, p=0.4731, respectively) or DFS (p=0.3282, p=0.1909, p=0.4111, p=0.5014, respectively). Clinical data on patient follow-up at Vanderbilt University Medical Center were retrospectively gathered via electronic medical records. The mean follow-up for disease-free survival and assessment of prostate cancer progression were 8.3 ± 2.4-y and 4.4 ± 3.9-y, respectively. The endpoints analyzed were recurrence-free survival (RFS) and diseasefree survival (DFS). Recurrence post-prostatectomy was classified as biochemical (which has been shown to be a poor predictor of overall survival in patients with localized prostate cancer treated with radical prostatectomy) [14], local or distant, and the most advanced recurrence type documented was assigned to each patient. Biochemical recurrence was defined as a prostate-specific antigen (PSA) detection of > 0.1 ng/ ml in at least two consecutive tests. DFS was defined as the length of time between the date of prostatectomy to the date of death or last follow-up. Conclusions Genotyping of Aurora Kinase A polymorphisms in prostate cancer samplesProstatectomy specimens were processed and genomic DNA extracted from deparaffinizedspecimens as described previously [15]. Purified genomic DNA was genotyped for the following haplotypetagging SNPs in the AURKA gene: rs1468055, rs8117896, rs2064863, and rs1468056. Haplotype-tagging SNPs (htSNPs) were selected using the ABI SNP Browser to cover SNPs with an r 2 of 0.90 or greater in the AURKA gene with a minor allele frequency (MAF) of at least 0.25. A total of 4 SNPs were selected and genotyped in our patient cohort. Allelic discrimination of these AURKA polymorphisms was performed using Taqman SNP genotyping assays (Applied Biosystems: and C_8947664_10 [rs1468056]). The fina...

show abstract

“…Several small studies have reported a correlation between SNPs in the TGFB1 gene and fibrosis, one form of late radiotherapy toxicity, in breast cancer patients [20][21][22]. In addition, a study of prostate cancer patients found significant associations between TGF genotype and certain toxicity end-points [23]. However, a recent study found no significant association between genotype and late clinical radiosensitivity in patients treated for gynaecological tumours [24].…”

mentioning

confidence: 99%

No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: Results from the RAPPER study

Barnett

Coles

Burnet

et al. 2010

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy

Cited by 61 publications

References 54 publications

Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients

Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients

The Aurora Kinase A Polymorphisms are not Associated with Recurrence-free Survival in Prostate Cancer Patients

No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: Results from the RAPPER study

Contact Info

Product

Resources

About